ROCKVILLE, Md., March 1, 2011 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that it will report its 2010 fourth quarter and full-year financial results on Tuesday, March 8, 2011, after the market close. The company will host a live webcast and conference call at 4:30 p.m. ET that day to discuss these results.

The webcast can be accessed at:

http://phx.corporate-ir.net/phoenix.zhtml?p=irol-eventDetails&c=100445&eventID=3766430

(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your browser. Remove the space if one exists) or via the Nabi Biopharmaceuticals website at .

If you do not have Internet access, the U.S./Canada call-in number is 866-356-4281 and the international call-in number is 617-597-5395. The passcode is 24178004. An audio replay will be available for U.S./Canada callers at 888-286-8010 and for international callers at 617-801-6888. The replay passcode is 23754777. An audio replay of this call will be available through March 15, 2011. The press release and an archived version of the webcast will be available on the company's website at .

About Nabi Biopharmaceuticals

Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAXÂ® (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit www.nabi.com.

CONTACT: Investor Relations 301-770-3099 www.nabi.com